We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Harrow
HROW
$1.45B
| $25.1K | ﹤0.01% |
+748
| New | +$33.1K |
|
|
VRE
452
DELISTED
Veris Residential
VRE
| $25.1K | ﹤0.01% |
+1,507
| New | +$26.3K |
|
453
Intellia Therapeutics
NTLA
$1.55B
| $24.9K | ﹤0.01% |
+2,139
| New | +$33.4K |
|
454
Immunocore
IMCR
$1.72B
| $24.5K | ﹤0.01% |
+831
| New | +$26.3K |
|
455
ANI Pharmaceuticals
ANIP
$1.83B
| $24.4K | ﹤0.01% |
+441
| New | +$25.3K |
|
|
ELME
456
Elme Communities
ELME
$144M
| $24.2K | ﹤0.01% |
+1,587
| New | +$26.3K |
|
457
Rocket Pharmaceuticals
RCKT
$351M
| $24.1K | ﹤0.01% |
+1,914
| New | +$28.8K |
|
458
Syndax Pharmaceuticals
SNDX
$1.73B
| $23.7K | ﹤0.01% |
+1,792
| New | +$30.7K |
|
|
ALEX
459
DELISTED
Alexander & Baldwin
ALEX
| $23.2K | ﹤0.01% |
+1,309
| New | +$24.7K |
|
460
Enliven Therapeutics
ELVN
$3.85B
| $23.1K | ﹤0.01% |
+1,026
| New | +$26.6K |
|
|
AAT
461
American Assets Trust
AAT
$1.48B
| $23.1K | ﹤0.01% |
+879
| New | +$24K |
|
462
Innoviva
INVA
$1.57B
| $22.8K | ﹤0.01% |
+1,314
| New | +$25.2K |
|
|
JBGS
463
JBG SMITH
JBGS
$820M
| $22.8K | ﹤0.01% |
+1,482
| New | +$24.8K |
|
464
ARS Pharmaceuticals
SPRY
$559M
| $21.5K | ﹤0.01% |
+2,041
| New | +$28.6K |
|
|
AVDL
465
DELISTED
Avadel Pharmaceuticals
AVDL
| $21.3K | ﹤0.01% |
+2,023
| New | +$24.6K |
|
466
Vir Biotechnology
VIR
$1.5B
| $21.2K | ﹤0.01% |
+2,892
| New | +$22.8K |
|
467
Zymeworks
ZYME
$1.67B
| $21.2K | ﹤0.01% |
+1,446
| New | +$20.2K |
|
|
AIV
468
Aimco
AIV
$383M
| $20.9K | ﹤0.01% |
+2,298
| New | +$19.8K |
|
|
PDM
469
Piedmont Realty Trust
PDM
$1.25B
| $20.5K | ﹤0.01% |
+2,236
| New | +$21.7K |
|
|
DEA
470
Easterly Government Properties
DEA
$1.15B
| $20.1K | ﹤0.01% |
+706
| New | +$22.4K |
|
|
NTST
471
NETSTREIT Corp
NTST
$2.1B
| $19.7K | ﹤0.01% |
+1,395
| New | +$21.7K |
|
472
Replimune Group
REPL
$455M
| $19.6K | ﹤0.01% |
+1,616
| New | +$19.6K |
|
473
Collegium Pharmaceutical
COLL
$1.17B
| $19.4K | ﹤0.01% |
+677
| New | +$22.4K |
|
|
ETNB
474
DELISTED
89bio
ETNB
| $19.3K | ﹤0.01% |
+2,469
| New | +$20.3K |
|
475
Anavex Life Sciences
AVXL
$250M
| $19.1K | ﹤0.01% |
+1,780
| New | +$13.7K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.